CASRN: 312-48-1
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of edrophonium during breastfeeding. However, because of its short half-life and quaternary ammonium structure, it is unlikely to be excreted into breastmilk or orally absorbed by the infant. Administering the drug just after breastfeeding and waiting 2 to 3 hours before breastfeeding again should avoid any adverse reactions in the infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Edrophonium
CAS Registry Number
312-48-1
Drug Class
- Breast Feeding
- Lactation
- Cholinesterase Inhibitors
- Diagnostic Agents
- Parasympathomimetics
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Publication Details
Publication History
Last Revision: December 3, 2018.
Copyright
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Publisher
National Institute of Child Health and Human Development, Bethesda (MD)
NLM Citation
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Edrophonium. [Updated 2018 Dec 3].